Although Johnson & Johnson's single-dose shot was approved in the United States months after shots from Pfizer and Moderna were cleared, its vaccine sales outlook still pales in comparison with its peers and reflects the widening gap in the global vaccine race.
The J&J vaccine, once touted as an important tool for vaccinations in hard-to-reach areas, has the least uptake in Europe among all the vaccines approved for use, and has also struggled in the United States.
J&J expects to produce 500 million to 600 million doses of the vaccine this year, chief financial officer Joseph Wolk told CNBC on Wednesday.
J&J raised its expectations for full-year sales, encouraged by a recovery in sales at its medical devices unit and higher demand for treatments such as psoriasis and Crohn's disease drug Stelara.
Sales at the company's medical devices unit rose 62.7% to $6.98 billion, boosting its second-quarter numbers.
The company now expects annual sales in a range of $93.8 billion to $94.6 billion including contribution from the vaccine, and $91.3 billion to $92.1 billion for the rest of the business.
It had previously forecast sales to come in between $90.6 billion and $91.6 billion.
J&J recorded $164 million in sales of its COVID-19 vaccine for the second quarter.
In the second quarter, J&J earned $2.48 per share, beating analysts' average estimate of $2.27 per share, according to IBES data from Refinitiv.
Shares of the company rose marginally to $169.97 before the opening bell. – Rappler.com